Medical Product Communications Act of 2017
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Mar 23, 2017)
Medical Product Communications Act of 2017
This bill amends the Federal Food, Drug, and Cosmetic Act to state that the intended use of a drug, biological product, or device shall be determined by the objective intent of the manufacturer and sponsor of such drug, biological product, or device, as demonstrated by statements contained in labeling, advertising, or analogous oral statements.
The intended use of these medical products shall not be determined by actual or constructive knowledge of the manufacturer or sponsor that these products will be used in a manner that varies from the use approved for marketing.
Additionally, the scientific exchange of information about these products shall not constitute labeling, advertising, or evidence of a new intended use.The bill sets forth the requirements for a scientific exchange.
What just happenedMar 24, 2017
Referred to the Subcommittee on Health.
Who’s behind it
- Introduced in HouseMar 23, 2017
- Mar 24, 2017Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Mar 23, 2017IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
Energy and Commerce Committee - Mar 23, 2017IntroReferralIntro-H
Introduced in House
- Mar 23, 2017IntroReferral1000
Introduced in House